Our purpose was to make a synthesis of the available evidence on the relative efficacy and safety of 2 drugeluting stents (DES)-sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)-in patients with coronary artery disease.
. Serious concerns have been raised regarding the longterm safety of these DES (10 -12) , although more comprehensive, patient-based meta-analyses do not justify these concerns (13, 14) . The SES and PES differ importantly with respect to polymer coating and antiproliferative drugs, which may impact on the risk of late adverse events associated with these devices. Recently, the results of 2 meta-analyses suggested that the risk of late thrombosis or death might be different between SES and PES (4, 9) . However, the difference has been implied by indirect comparisons from trials comparing SES and PES with bare-metal stents separately (4, 9) . Thus, it remains uncertain whether there are any differences between SES and PES with regard to their long-term safety profile. Notwithstanding, a prior meta-analysis including 6 trials with 3,669 patients followed-up for up to 1 year has shown that SES are superior to PES in reducing the risk of restenosis (15) . Whether the benefit of the SES is maintained beyond this period also remains unknown.
Direct comparison meta-analysis of randomized trials has the potential to increase power and improve precision of treatment effects (16) . Availability of individual patient data is the "gold standard" to analyze time-to-event or survival data (17) . Therefore, we performed a comprehensive metaanalysis with a large use of individual patient data from all clinical trials that have evaluated the long-term outcomes after coronary implantation of SES and PES.
Methods

Clinical trial selection.
Randomized head-to-head trials of SES (Cypher, Cordis, Johnson & Johnson, Miami Lakes, Florida) and PES (TAXUS, Boston Scientific Corp, Natick, Massachusetts) in patients with coronary artery disease were identified through searches of the PubMed database, U.S. National Institute of Health, Cochrane Central Register of Controlled Trials, and the proceedings of the American Heart Association, American College of Cardiology, and European Society of Cardiology. Internetbased sources of information on the results of clinical trials in cardiology were also searched. Other data sources included reference lists of retrieved articles and pertinent reviews and editorials from leading medical journals. The last search was performed in April 2007.
Sixteen randomized clinical trials were included in this meta-analysis (18 -33) . The main characteristics of these trials are displayed in Table 1 and their definitions of events in Table 2 . Outcome variables. The primary efficacy end point of this meta-analysis was the need for reintervention (target lesion revascularization). The primary safety end point of this meta-analysis was stent thrombosis. Secondary end points were death and recurrent MI. All trials reported blind adjudication of adverse events made by the same events committee throughout the follow-up period. Event definitions for each trial are listed in Table 2 . Data collection and assessment of quality. Principal investigators or sponsors of each eligible trial were asked to complete electronic datasheets encompassing the following data for each individual patient: date of randomization; treatment assigned by randomization; death, MI, reintervention, stent thrombosis, and their respective date of occurrence; and date of last follow-up. Data for surviving patients were censored at the date of last contact. The principal investigators from 11 of the 16 randomized trials agreed to provide individual patient data (18,20,21,23-26,28 -30,32) . Summary outcome data of the remaining 5 trials were extracted from the respective publications or presentations or obtained directly from the investigators (19, 22, 27, 31, 33) .
The following methodological criteria were evaluated for all included trials: adequacy of allocation concealment, performance of the analysis according to the intention-totreat principle, and blind assessment of the outcomes of interest. No summary score was used to identify low or high quality trials; we did not perform weighting by quality scores as this practice has not been recommended by some (34 -36) . Statistical analysis. Treatment effects, expressed as hazard ratios (HRs) or relative risks (for trials from which no individual patient data were available) for SES and PES, were first estimated for each trial and then combined using standard meta-analytic methods. Survival analyses were performed for each trial using the Mantel-Cox method, which is not based on the proportional hazards assumption; the log-rank test was used to calculate HRs with 95% confidence intervals (CIs). Trials in which the event of interest was not observed in any of the treatment groups were not included in the analysis of that event. For trials in which only one of the treatment groups had no events of interest, the treatment effect estimate and its standard error were approximated from 2 ϫ 2 contingency tables after adding 0.5 to each cell (37) . We used the Cochran test to assess heterogeneity across trials. Also, we calculated the I2 statistic to measure the consistency between trials with values of 25%, 50%, and 75% representing low, moderate, and high degrees of heterogeneity, respectively (38) . The HRs from individual trials were pooled using both the fixed effects Mantel-Haenszel model (39) and the random effects DerSimonian and Laird model (40) . If no heterogeneity is present, both models yield similar results. Herein, we report the results from the random-effects model. All p values are 2-sided. Statistical significance was assumed for p Ͻ 0.05. Statistical analysis was performed using the Stata software, version 9.2 (Stata Corp., College Station, Texas). Exploratory survival curves, which are presented as simple, nonstratified Kaplan-Meier curves across all trials, are con- 
Results
A total of 16 randomized trials including 8,695 patients were analyzed ( Table 1 ). The patients were representative of the whole clinical spectrum of coronary artery disease. Individual patient data were available from 11 trials including 5,562 patients who were followed up for a median of 24.3 months (25th, 75th percentiles: 18.4, 28.7 months) in the SES group and 24.3 months (25th, 75th percentiles: 18.3, 28.5 months) in the PES group (p ϭ 0.51) (18,20,21,23-26,28 -30,32) .
Reintervention, the primary efficacy end point, was needed in 295 patients in the SES group versus 380 patients in the PES group. Allocation to the SES group was associated with a hazard ratio (HR) for reintervention of 0.74 (95% confidence interval [CI] 0.63 to 0.87, p Ͻ 0.001) (Fig. 1A) . There was no significant heterogeneity across trials (p ϭ 0.39). The sensitivity analysis yielded HRs that ranged from 0.69 (95% CI 0.59 to 0.82) to 0.78 (95% CI 0.66 to 0.92) and were not significantly different from the overall HR (p Ն 0.58). There was no significant interaction between the treatment effect and inclusion of follow-up angiography in the study protocol (p ϭ 0.10). When the analysis was confined to the trials for which individual patient data were available, SES were associated with a HR for reintervention of 0.72 (95% CI 0.61 to 0.86, p Ͻ 0.001). Within the first year, the HR was 0.70 (95% CI 0.57 to 0.85, p Ͻ 0.001); after the first year, the HR was 0.79 (95% CI 0.58 to 1.09, p ϭ 0.15). Figure 1B shows the probability curves of reintervention: the 30-month probability of reintervention was 9.5% in the SES group and 12.7% in the PES group. Stent thrombosis, the primary safety end point, was observed in 53 patients in the SES group versus 82 patients in the PES group. Allocation to the SES group was associated with a HR for stent thrombosis of 0.66 (95% CI 0.46 to 0.94, p ϭ 0.02) ( Fig. 2A) . There was no significant heterogeneity across trials (p ϭ 0.93). The sensitivity analysis yielded HRs that ranged from 0.55 (95% CI 0.36 to 0.84) to 0.75 (95% CI 0.51 to 1.09) and were not significantly different from the overall HR (p Ն 0.52). When the analysis was confined to the trials End Point Definitions in Each Trial Included in the Meta-Analysis Figure 2B shows the probability curves of stent thrombosis: the 30-month probability of stent thrombosis was 1.2% in the SES group and 2.6% in the PES group. As also shown by the curves, the difference was more evident after the first 12 months. In the SES group, 169 patients died as compared with 173 patients in the PES group. Allocation to the SES group was associated with a HR for death of 0.92 (95% CI 0.74 to 1.13, p ϭ 0.43) (Fig. 3A) . There was no significant I 2 =6%, P (Heterogeneity) = 0.39 
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heterogeneity across trials (p ϭ 0.98). The sensitivity analysis yielded HRs that ranged from 0.89 (95% CI 0.72 to 1.11) to 0.94 (95% CI 0.75 to 1.16) and were not significantly different from the overall HR (p Ն 0.85). When the analysis was confined to the trials for which individual patient data were available, SES were associated with a HR for death of 0.92 (95% CI 0.73 to 1.17, p ϭ 0.50). Within the first year, the HR was 1.02 (95% CI 0.73 to 1.45, p ϭ 0.89); after the first year, the HR was 0.84 (95% CI 0.61 to 1.16, p ϭ 0.29). Figure 3B shows the probability curves of death: the 30-month probability of death was 6.0% in the SES group and 6.3% in the PES group. Myocardial infarction occurred in 178 patients in the SES group versus 205 patients in the PES group. Allocation to the SES group was associated with a HR for MI of 0.84 (95% CI 0.69 to 1.03, p ϭ 0.10) (Fig. 4A) .
There was no significant heterogeneity across trials (p ϭ 0.99). The sensitivity analysis yielded HRs that ranged from 0.80 (95% CI 0.64 to 0.99) to 0.87 (95% CI 0.69 to 1.10) and were not significantly different from the overall HR (p Ն 0.74). When the analysis was confined to the trials for which individual patient data were available, SES were associated with a HR for MI of 0.81 (95% CI 0.64 to 1.02, p ϭ 0.07). Within the first year, the HR was 0.91 (95% CI 0.71 to 1.17, p ϭ 0.46); after the first year, the HR was 0.45 (95% CI 0.25 to 0.80, p ϭ 0.006). After the first year, 18 patients in the SES group and 36 patients in the PES group incurred an MI. Figure 4B shows the probability curves of MI: the 30-month probability of MI was 5.3% in the SES group and 7.1% in the PES group. As also shown by the curves, the difference became more evident after the first 12 months. Regarding the composite of death or MI, SES were associated with a HR of 0.86 (95% CI 0.72 to 1.01, p ϭ 0.07).
Discussion
This meta-analysis compared long-term clinical outcomes after implantation of SES versus PES in a large population of patients with various clinical presentations of coronary artery disease. Compared with PES, SES significantly reduce the risk of reintervention and stent thrombosis without significantly impacting the risk of death or MI. Three limitations should be acknowledged before commenting on the findings of this study. First, we were only able to obtain individual patient data from two-thirds of the trials. Completeness of patient-level data may increase the accuracy of the analysis. It is, however, reassuring that the treatment effects calculated for the entire population are in accordance with those obtained when individual patient data was analyzed. Second, 10 of the 16 trials included in this meta-analysis had a protocol-mandated follow-up angiography. This may exaggerate the risk of the occulostenotic reflex and lead to an increase in the number of reinterventions, although no significant interaction could be found between this study design feature and treatment effect. In addition, the fact that the difference in the risk of reintervention between the 2 DES types persisted even beyond the scheduled time for follow-up angiography (6 to 9 months) does not support a significant impact of protocolmandated follow-up angiography on the treatment effect in favor of the SES observed in this meta-analysis. Third, all trials were open-label trials due to the impossibility of blinding completely different devices coming from 2 different manufacturers. Although all reported events went through a blind adjudication process, these limitations might have had an impact on the evaluation of at least 1 of the events of interest, the reintervention.
Sirolimus-eluting stents and PES are the most widely used drug-eluting stents to date. Delayed healing characterized by persistent fibrin deposition, poorer endothelialization, and local hypersensitivity reaction are some of the mechanisms put forward for the explanation of the late occurrence of thrombosis-related events with drugeluting stents (41) . There have been reports that these phenomena are more pronounced with PES than SES, at least in the presence of overlapping stents (42) . We observed that patients treated with SES had a 34% reduction in the hazard of stent thrombosis relative to patients treated with PES. This finding, coupled with the fact that SES are associated with less late loss than PES (24, 25, 29, 30) , does not support the recently reported hypothesis that a greater late loss may have a protective role against stent thrombosis (12) . Notably, the risk of both stent thrombosis and MI with PES was particularly higher after the first year. A different susceptibility to thrombosis after cessation of clopidogrel treatment between the 2 DES may explain the higher incidence of stent thrombosis with PES. A higher risk of late stent thrombosis with PES versus SES was also recently observed in a registry of a large series of patients (43) . Although late stent thrombosis was numerically more frequent with PES, this complication was encountered with both DES types and requires maximal attention to improve long-term safety. These findings may indicate that patients who receive drug-eluting stents require a period of dual antiplatelet therapy longer than that currently recommended (44) ; this may be particularly important for patients who receive PES. We must acknowledge, however, 2 factors that may interfere with the results of the analysis of stent thrombosis. First, only recently there has been a strong interest in finding a common definition of stent thrombosis, which can be used universally in all drug-eluting stent trials. Although this would constitute an important step forward for future trials, the value of the retrospective application of new definitions for previously conducted trials is not proven. Second, although the recommended duration of clopidogrel therapy in each trial was known, we did not have information about the actual length of this therapy and related compliance for individual patients.
Conclusions
The SES are superior to PES in terms of a significant reduction of the risk of reintervention and stent thrombosis. The risk of death was not significantly different between the 2 DES, but there was a trend toward a higher risk of MI with PES, especially after the first year from the procedure.
